A rheumatology practice asked us why its infusion revenue had drifted down over a year while its infusion volume had not. The answer took an afternoon. About a fifth of their infliximab claims had gone out with the administered dose only and no line for the discarded amount, so the wasted portion of every vial was simply never billed. Another tenth had been returned by the Medicare contractor as unprocessable because the single line had neither a JW nor a JZ modifier, and about half of those had never been resubmitted. Nobody had made a coding mistake in the sense of picking the wrong code. They had just stopped billing part of what they bought.
Drug charges are one of the quietest sources of revenue leakage in office practice, because the drug is a supply, the nurse administers it, and the charge depends on arithmetic that nobody checks: the vial size, the dose, the billing unit of the HCPCS code, and since 2023 a modifier that says whether anything was thrown away. Get any one of those wrong and the claim either pays less than it should or does not pay at all.
This article explains the JW and JZ modifiers, the billing-unit arithmetic, and the three-report audit we run to find the missing drug revenue in any practice that gives injections or infusions.
Key takeaways
- For Medicare Part B, every separately payable drug from a single-dose container must carry either JW (some was discarded, billed on its own line) or JZ (nothing was discarded); since October 2, 2023, claims without one are returned unprocessable.
- Multi-dose vials never take JW or JZ, and drugs that are packaged into a procedure payment are not billed at all.
- Most drug underpayments are unit errors: the HCPCS billing unit is rarely the same as the dose the nurse wrote down.
- The discarded amount is payable, but only if the record documents it and the claim bills it on a JW line.
- Three reports (administration without drug, drug without administration, units versus dose) find most of the leakage in an afternoon.
The JW and JZ modifier rules, and where they came from
Medicare has required the JW modifier since January 1, 2017 to report the amount of a drug discarded from a single-dose container or single-use package that is separately payable under Part B. The discarded amount goes on its own claim line with JW, and the record must show how much was discarded. Then, in the calendar year 2023 physician fee schedule final rule, CMS added the JZ modifier to attest that no amount was discarded. The JZ requirement took effect July 1, 2023, and from October 1, 2023 Medicare contractors began editing claims: a single-dose drug line with neither modifier is returned as unprocessable, which means no adjudication, no appeal rights, and a new claim.
The reason CMS wanted the data is the discarded drug refund provision in the Infrastructure Investment and Jobs Act of November 2021, which requires manufacturers to refund Medicare for discarded amounts of certain single-dose drugs above a 10 percent threshold. CMS calculates the refunds from JW lines, so it needs every claim to say either how much was wasted or that nothing was. Your modifier is somebody else's invoice.
The scope matters. JW and JZ apply to drugs that are separately payable under Part B and come in single-dose containers or single-use packages. They do not apply to multi-dose vials, because the remainder is not discarded; it is used for the next patient. They do not apply to drugs whose payment is packaged into the procedure, and they do not apply to Part D drugs or inpatient drugs. Commercial payers and Medicaid programs have adopted the modifiers to varying degrees; check each payer's policy, but billing them consistently is rarely wrong.
The arithmetic that produces most drug underpayments
Glossary line: a HCPCS Level II J code describes a drug in a fixed billing unit, for example J1745, infliximab, 10 mg. The units field on the claim is the number of those billing units, not milligrams and not vials. Most drug underpayments we find are a mismatch between the dose in the chart and the units on the claim, in one of three directions: the biller entered the milligram dose as units when the unit is 10 mg (a tenfold overbilling that gets caught by medically unlikely edits), entered 1 unit meaning "one vial" when the vial holds several units (a large underbilling that nothing catches), or entered the administered dose correctly and forgot the wasted portion.
| Drug (common office use) | HCPCS | Billing unit | Example dose | Units to bill | Container | Modifier |
|---|---|---|---|---|---|---|
| Ceftriaxone | J0696 | Per 250 mg | 1 g intramuscular | 4 | Single-dose vial (1 g) | JZ if fully used |
| Ketorolac | J1885 | Per 15 mg | 60 mg intramuscular | 4 | Single-dose vial (60 mg/2 mL) | JZ |
| Methylprednisolone acetate | J1030 | Per 40 mg | 80 mg joint injection | 2 | Single-dose or multi-dose, check the vial | JZ or JW only if single-dose |
| Triamcinolone acetonide | J3301 | Per 10 mg | 40 mg joint injection | 4 | Usually multi-dose vial | None for multi-dose |
| Ondansetron | J2405 | Per 1 mg | 4 mg intravenous | 4 | Single-dose vial (4 mg/2 mL) | JZ |
| Denosumab (osteoporosis) | J0897 | Per 1 mg | 60 mg subcutaneous | 60 | Single-dose prefilled syringe | JZ |
| Infliximab | J1745 | Per 10 mg | 350 mg infusion from 100 mg vials | 35 administered plus 5 JW | Single-dose vials (4 opened) | JW on the discarded line |
| Cyanocobalamin (B12) | J3420 | Up to 1,000 mcg | 1,000 mcg intramuscular | 1 | Usually multi-dose vial | None for multi-dose |
Two cautions on the table. Whether a product is single-dose or multi-dose is a property of the specific vial you bought, not the drug name; the same steroid comes both ways. And Medicaid programs and many commercial payers also require the 11-digit National Drug Code and the NDC unit of measure on the claim line, which is a separate field from the HCPCS units and another common rejection when the pharmacy changes suppliers.
A worked infusion
A 54-year-old Medicare patient receives infliximab, 5 mg per kilogram, weighing 70 kg, so a 350 mg dose. The practice stocks 100 mg single-dose vials. The nurse reconstitutes four vials (400 mg), administers 350 mg, and documents "50 mg discarded" in the infusion record. The claim carries two drug lines: J1745, 35 units, for the administered amount, and J1745-JW, 5 units, for the discarded amount, plus the infusion administration code 96413 for the first hour and 96415 for each additional hour as documented.
Medicare pays separately payable Part B drugs at the average sales price plus 6 percent, reduced in practice by the 2 percent sequestration, and it pays both lines. The JW line for 50 mg of infliximab is worth a meaningful amount on every visit, and it was the line the rheumatology practice had stopped billing. Across a year of infusions the lost wastage alone came to tens of thousands of dollars, before the unprocessable returns that were never resubmitted.
Had the nurse used 350 mg from a 350 mg dose drawn from vials with nothing left over (say the dose had been 400 mg), the claim would carry one line, J1745, 40 units, JZ. Had the record not documented the discarded amount, the JW line would not be supportable and the practice could bill only the 35 units, with JZ absent, and the claim would return unprocessable. Documentation of waste is not paperwork; it is the charge.
The three-report audit
We run this for any practice with an injection or infusion volume, and it takes an afternoon with a practice management system report writer.
Report one: administration codes without a drug. Pull every 96372, 96374, 96365, 96413 and their add-ons for the last twelve months and match by patient and date to a J code. Every administration line without a drug line is either a free drug (a sample, a patient-supplied drug, a vaccine billed under a CPT vaccine code) or a missed charge. In our experience, a third to a half are missed charges.
Report two: drugs without an administration code, and single-dose drug lines without JW or JZ. The first finds injections where the nurse's work was never billed; the second finds claims that were returned unprocessable and may never have been resubmitted. Cross-check the second list against the clearinghouse rejection reports.
Report three: units versus dose. Sample fifty drug lines, pull the administration record for each, convert the documented dose to billing units using the HCPCS descriptor, and compare. Also compare the documented waste to the JW units. A mismatch rate above 5 percent means the charge capture process needs a unit conversion table at the point of entry, which most EHR medication administration modules can carry.
Then fix the workflow rather than the claims. Load a drug charge table in the EHR that maps each stocked product (by NDC) to its HCPCS code, billing unit, single or multi-dose status, and default modifier, so the nurse records milligrams and the system produces units and modifiers. Make "amount discarded" a required field for single-dose products. And make sure the billing team's unprocessable-return worklist is worked weekly; a returned claim is not a denial and will not show in the denial report. Practices that want the audit done for them can start with an RCM audit, which includes drug charge reconciliation, and our medical billing team builds the drug charge table as part of onboarding infusion practices.
Questions we hear
Can we bill wastage if we gave two patients doses from one single-dose vial?
No, and you should not be doing it. Single-dose vials are labeled for one patient for infection control reasons, and Medicare pays wastage on the assumption that the remainder was discarded. If you split a single-dose vial between patients, bill each patient only the administered amount and bill no JW line. Better, buy vial sizes that match your dosing.
Does JW or JZ go on the administration code?
No. Both modifiers belong on the drug line only. The administration code carries its own modifiers where needed (for example, 25 on a same-day E/M visit belongs on the E/M code, not the injection). Putting JZ on 96372 gets a CO-4 denial and does not satisfy the drug line edit.
Our commercial payers do not require JZ. Should we send it anyway?
We do. A consistent rule across payers is easier to train and audit than payer-specific exceptions, and payers that ignore the modifier do not deny for its presence. The one thing to check is whether a particular payer wants the wastage on a separate line with JW or combined into the administered line; a few commercial policies differ from Medicare on that point.
What to do this week
- Run report one (administration codes without a drug line) for the last twelve months and count the missed charges.
- Run report two and match single-dose drug lines lacking JW or JZ against clearinghouse returns; resubmit the ones still inside timely filing.
- Sample fifty drug lines against the administration record and calculate your unit mismatch rate.
- Build the drug charge table by NDC with HCPCS code, billing unit, container type and default modifier, and load it into the EHR.
- Make "amount discarded" a required field for single-dose products in the medication administration record.
- Add unprocessable returns to the weekly worklist so they are not lost between the rejection report and the denial report.
